<DOC>
	<DOCNO>NCT02205047</DOCNO>
	<brief_summary>The purpose study find whether either trastuzumab combination trastuzumab pertuzumab standard chemotherapy show activity gastro-oesophageal adenocarcinoma standard chemotherapy give surgery safely administer .</brief_summary>
	<brief_title>Neoadjuvant Study Using Trastuzumab Trastuzumab With Pertuzumab Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description>This randomized phase II trial internal control . The randomization 1:2:2 randomization ( control : experimental arm 1 : experimental arm 2 ) . Potentially eligible patient screen centrally HER-2 status . After confirmation HER-2 positive disease , eligible patient centrally randomize EORTC randomization system . A minimization technique use random treatment allocation three treatment arm . Stratification do histological subtype ( intestinal/non-intestinal ) ; Korea versus Europe ; stage II versus III ; node positive versus node negative .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven , gastric gastroesophageal ( GE ) junction adenocarcinoma ( Siewert IIII ) Patient medically fit gastrectomy/oesophagogastrectomy decide investigator Age â‰¥ 18 year WHO performance status 0 1 HER2 overexpression Amenable gastrectomy/oesophagectomy The cardiac ejection fraction ( LVEF ) , determine echocardiography , multiple gated acquisition scan ( MUGA ) cardiac MRI least 50 % Adequate organ function write informed consent For woman postmenopausal ( &gt; 12 month nontherapy induce amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine contraceptive method result failure rate &lt; 1 % per year treatment period least 12 month last treatment dose For men : agreement remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 12 month last dose study treatment . Abstinence acceptable line prefer usual lifestyle patient . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Absence distant metastasis CT scan thorax abdomen prior chemo antibody therapy history significant cardiac disease current uncontrolled hypertension know hypersensitivity component trastuzumab , pertuzumab , cisplatin , 5followup capecitabine know dihydropyrimidine dehydrogenase ( DPD ) deficiency ongoing concomitant use antiviral drug sorivudine chemically related analog , brivudine chronic treatment highdose intravenous corticosteroid previous malignancy within last 5 year , exception adequately treat cervical carcinoma situ , localize nonmelanoma skin cancer , curatively treated cancer without impact patient 's overall prognosis accord judgment investigator . psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neoadjuvant chemotherapy</keyword>
</DOC>